Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
Gottfried E. Konecny, Teodora Kolarova, Neil A. O’Brien, et al.
Molecular Cancer Therapeutics (2013) Vol. 12, Iss. 5, pp. 632-642
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Classification of endometrial carcinoma: more than two types
Rajmohan Murali, Robert A. Soslow, Britta Weigelt
The Lancet Oncology (2014) Vol. 15, Iss. 7, pp. e268-e278
Closed Access | Times Cited: 581
FGF Receptors: Cancer Biology and Therapeutics
Masaru Katoh, Hitoshi Nakagama
Medicinal Research Reviews (2013) Vol. 34, Iss. 2, pp. 280-300
Closed Access | Times Cited: 534
Targeting FGFR Signaling in Cancer
Mehdi Touat, Ecaterina Ileana, Sophie Postel‐Vinay, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 12, pp. 2684-2694
Closed Access | Times Cited: 452
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Rodrigo Dienstmann, Jordi Rodón, Aleix Prat, et al.
Annals of Oncology (2013) Vol. 25, Iss. 3, pp. 552-563
Open Access | Times Cited: 342
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Noah A. Brown, Delphine C.M. Rolland, Jonathan B. McHugh, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 21, pp. 5517-5526
Open Access | Times Cited: 249
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 189
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Kai Hung Tiong, Li Yen Mah, Chee‐Onn Leong
APOPTOSIS (2013) Vol. 18, Iss. 12, pp. 1447-1468
Open Access | Times Cited: 160
Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)
Masaru Katoh
International Journal of Molecular Medicine (2013) Vol. 32, Iss. 4, pp. 763-767
Open Access | Times Cited: 148
Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction
Edward Carter, Abbie E. Fearon, Richard Grose
Trends in Cell Biology (2014) Vol. 25, Iss. 4, pp. 221-233
Closed Access | Times Cited: 146
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten, Maria Schwaederlé, Razelle Kurzrock
Cancer and Metastasis Reviews (2015) Vol. 34, Iss. 3, pp. 479-496
Open Access | Times Cited: 121
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
Noah A. Brown, Bryan L. Betz
Biomarkers in Cancer (2015) Vol. 7s2, pp. BIC.S29329-BIC.S29329
Open Access | Times Cited: 106
Future applications of FGF/FGFR inhibitors in cancer
Gaia C. Ghedini, Roberto Ronca, Marco Presta, et al.
Expert Review of Anticancer Therapy (2018) Vol. 18, Iss. 9, pp. 861-872
Closed Access | Times Cited: 89
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Gottfried E. Konecny, Neil J. Finkler, Agustin A. García, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 6, pp. 686-694
Closed Access | Times Cited: 85
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
Sébastien Taurin, Chieh-Hsiang Yang, Maria Reyes, et al.
International Journal of Gynecological Cancer (2017) Vol. 28, Iss. 1, pp. 152-160
Open Access | Times Cited: 78
The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study
Tom D. Bunney, Shunzhou Wan, Nethaji Thiyagarajan, et al.
EBioMedicine (2015) Vol. 2, Iss. 3, pp. 194-204
Open Access | Times Cited: 71
FGFR signalling in women's cancers
Abbie E. Fearon, Charlotte R. Gould, Richard Grose
The International Journal of Biochemistry & Cell Biology (2013) Vol. 45, Iss. 12, pp. 2832-2842
Closed Access | Times Cited: 67
Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity
Camillo Porta, Palma Giglione, Wanda Liguigli, et al.
Future Oncology (2015) Vol. 11, Iss. 1, pp. 39-50
Closed Access | Times Cited: 54
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Wei Jiang, Meiju Ji
Seminars in Cancer Biology (2019) Vol. 59, pp. 3-22
Closed Access | Times Cited: 47
Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma
Alessio Ardizzone, Sarah Adriana Scuderi, Dario Giuffrida, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3825-3825
Open Access | Times Cited: 44
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Y. Jeske, Shamshad Ali, Sara A. Byron, et al.
Gynecologic Oncology (2017) Vol. 145, Iss. 2, pp. 366-373
Open Access | Times Cited: 48
Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia
Stefanie Krick, Nathalie Baumlin, S. Paredes Aller, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 46
Therapeutic uses of FGFs
Jun Zhang, Yang Li
Seminars in Cell and Developmental Biology (2015) Vol. 53, pp. 144-154
Closed Access | Times Cited: 42
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Leisl Packer, Xinyan Geng, Vanessa Bonazzi, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 4, pp. 637-648
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top